{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:45:37Z","timestamp":1788417937455,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.intimp.2020.106480","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T06:15:14Z","timestamp":1586499314000},"page":"106480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The off-label uses profile of tofacitinib in systemic rheumatic diseases"],"prefix":"10.1016","volume":"83","author":[{"given":"Zichu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2020.106480_b0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"Jaks and stats in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2020.106480_b0010","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/JLB.5RI0218-084R","article-title":"Translational and clinical advances in jak-stat biology: the present and future of jakinibs","volume":"104","author":"Gadina","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2020.106480_b0015","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2020.106480_b0020","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to tnf inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"745\u201353","key":"10.1016\/j.intimp.2020.106480_b0025","article-title":"Janus kinase inhibitors in dermatology: a systematic review","volume":"76","author":"Shreberk-Hassidim","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2020.106480_b0030","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.cgh.2018.11.038","article-title":"Rapid onset of tofacitinib induction therapy for the treatment of ulcerative colitis","volume":"17","author":"Griller","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2020.106480_b0035","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2020.106480_b0040","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11926-011-0166-x","article-title":"Pathogenesis of dermatomyositis: role of cytokines and interferon","volume":"13","author":"Kao","year":"2011","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.intimp.2020.106480_b0045","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.intimp.2020.106480_b0050","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/rheumatology\/key366","article-title":"Management of refractory cutaneous dermatomyositis: Potential role of janus kinase inhibition with tofacitinib","volume":"58","author":"Moghadam-Kia","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2020.106480_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2016.08.009","article-title":"A case of refractory dermatomyositis responsive to tofacitinib","volume":"46","author":"Paik","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.intimp.2020.106480_b0060","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.intimp.2020.106480_b0065","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.jid.2018.03.510","article-title":"Tofacitinib for recalcitrant cutaneous dermatomyositis","volume":"138","author":"Alsarheed","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2020.106480_b0070","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1097\/RHU.0000000000000807","article-title":"Tofacitinib for the treatment of refractory polymyositis","volume":"25","author":"Babaoglu","year":"2019","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2020.106480_b0075","first-page":"1","article-title":"Successful treatment for refractory interstitial lung disease and pneumomediastinum with multidisciplinary therapy including tofacitinib in a patient with anti-MDA5 antibody-positive dermatomyositis","author":"Kato","year":"2020","journal-title":"JCR: J. Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2020.106480_b0080","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awz293","article-title":"Treatment of anti-mda5 autoantibody-positive juvenile dermatomyositis using tofacitinib","volume":"142","author":"Sabbagh","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.intimp.2020.106480_b0085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaut.2019.03.003","article-title":"Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the janus-kinase inhibitor tofacitinib - a report of two cases","volume":"100","author":"Wendel","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2020.106480_b0090","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2020.106480_b0095","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2020.106480_b0100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/archderm.140.3.365","article-title":"Calcinosis cutis complicating adult-onset dermatomyositis","volume":"140","author":"Weinel","year":"2004","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.intimp.2020.106480_b0105","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.3390\/ijms19092820","article-title":"Nucleus, mitochondrion, or reticulum? STAT3 \u00e0 La Carte","volume":"19","author":"Avalle","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2020.106480_b0110","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ken405","article-title":"Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis","volume":"48","author":"Badea","year":"2009","journal-title":"Rheumatology"},{"issue":"Suppl 10","key":"10.1016\/j.intimp.2020.106480_b0115","first-page":"997","article-title":"The effects of the jak-stat signal pathway inhibition on collagen biosynthesis in fibroblast cell culture [abstract]","volume":"70","author":"\u015eahi\u0307n","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2020.106480_b0120","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/art.34500","article-title":"Jak-2 as a novel mediator of the profibrotic effects of transforming growth factor beta in systemic sclerosis","volume":"64","author":"Dees","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"Suppl","key":"10.1016\/j.intimp.2020.106480_b0125","article-title":"Pharmacological inhibition of jak\/stat signaling by tofacitinib prevents organ fibrosis: Novel therapy for scleroderma [abstract]","volume":"139","author":"Bhattacharyya","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2020.106480_b0130","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","article-title":"Activation of stat3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis","volume":"8","author":"Chakraborty","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2020.106480_b0135","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.14876","article-title":"The use of jak inhibitors in the treatment of progressive systemic sclerosis","volume":"32","author":"Deverapalli","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2020.106480_b0140","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/03009742.2017.1387673","article-title":"Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis","volume":"47","author":"Komai","year":"2018","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.intimp.2020.106480_b0145","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jdcr.2017.12.003","article-title":"Treatment of generalized deep morphea and eosinophilic fasciitis with the janus kinase inhibitor tofacitinib","volume":"4","author":"Kim","year":"2018","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.intimp.2020.106480_b0150","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/13543784.2019.1551358","article-title":"The jakinibs in systemic lupus erythematosus: Progress and prospects","volume":"28","author":"Mok","year":"2019","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.intimp.2020.106480_b0155","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13075-016-1034-x","article-title":"Jak3-stat pathway blocking benefits in experimental lupus nephritis","volume":"18","author":"Ripoll","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2020.106480_b0160","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12865-017-0225-9","article-title":"Jak inhibitor has the amelioration effect in lupus-prone mice: The involvement of ifn signature gene downregulation","volume":"18","author":"Ikeda","year":"2017","journal-title":"BMC Immunol."},{"key":"10.1016\/j.intimp.2020.106480_b0165","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/art.39818","article-title":"Tofacitinib ameliorates murine lupus and its associated vascular dysfunction","volume":"69","author":"Furumoto","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2020.106480_b0170","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3109\/14397595.2015.1069473","article-title":"Tofacitinib can decrease anti-DNA antibody titers in inactive systemic lupus erythematosus complicated by rheumatoid arthritis","volume":"26","author":"Yamamoto","year":"2016","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.intimp.2020.106480_b0175","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/annrheumdis-2019-215455","article-title":"Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre","volume":"78","author":"You","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2020.106480_b0180","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.autrev.2012.10.006","article-title":"Type i interferons in sjogren's syndrome","volume":"12","author":"Yao","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2020.106480_b0185","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3389\/fimmu.2019.00281","article-title":"Single cell based phosphorylation profiling identifies alterations in toll-like receptor 7 and 9 signaling in patients with primary sjogren's syndrome","volume":"10","author":"Davies","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2020.106480_b0190","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.autrev.2016.09.001","article-title":"Dry eye disease and uveitis: a closer look at immune mechanisms in animal models of two ocular autoimmune diseases","volume":"15","author":"Bose","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2020.106480_b0195","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1167\/iovs.19-26928","article-title":"Therapeutic effects of stat3 inhibition on experimental murine dry eye","volume":"60","author":"Qu","year":"2019","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.intimp.2020.106480_b0200","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.ophtha.2012.01.028","article-title":"Tofacitinib (cp-690,550), a janus kinase inhibitor for dry eye disease: Results from a phase 1\/2 trial","volume":"119","author":"Liew","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.intimp.2020.106480_b0205","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.ophtha.2012.03.017","article-title":"Immunomodulatory effect of the topical ophthalmic janus kinase inhibitor tofacitinib (cp-690,550) in patients with dry eye disease","volume":"119","author":"Huang","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.intimp.2020.106480_b0210","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/annrheumdis-2015-208371","article-title":"Blocking interferon gamma reduces expression of chemokines cxcl9, cxcl10 and cxcl11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis","volume":"75","author":"Corbera-Bellalta","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2020.106480_b0215","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1161\/CIRCULATIONAHA.117.030423","article-title":"Inhibition of jak-stat signaling suppresses pathogenic immune responses in medium and large vessel vasculitis","volume":"137","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.intimp.2020.106480_b0220","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.autrev.2016.02.015","article-title":"Polyarteritis nodosa: a contemporary overview","volume":"15","author":"De Virgilio","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2020.106480_b0225","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1136\/annrheumdis-2016-209330","article-title":"Tofacitinib for polyarteritis nodosa: a tailored therapy","volume":"75","author":"Rimar","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2020.106480_b0230","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11926-019-0848-3","article-title":"Takayasu arteritis: recent developments","volume":"21","author":"Zaldivar Villon","year":"2019","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.intimp.2020.106480_b0235","doi-asserted-by":"crossref","first-page":"4246965","DOI":"10.1155\/2018\/4246965","article-title":"Gene expression profiling in behcet's disease indicates an autoimmune component in the pathogenesis of the disease and opens new avenues for targeted therapy","volume":"2018","author":"Puccetti","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.intimp.2020.106480_b0240","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/gene.2014.64","article-title":"Activation of the jak\/stat pathway in behcet's disease","volume":"16","author":"Tulunay","year":"2015","journal-title":"Genes Immun."},{"key":"10.1016\/j.intimp.2020.106480_b0245","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1038\/s41598-017-04109-6","article-title":"Identification of jak-stat signaling involvement in sarcoidosis severity via a novel microrna-regulated peripheral blood mononuclear cell gene signature","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2020.106480_b0250","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.gene.2016.09.037","article-title":"Bioinformatics analysis of gene expression profile data to screen key genes involved in pulmonary sarcoidosis","volume":"596","author":"Li","year":"2017","journal-title":"Gene"},{"key":"10.1016\/j.intimp.2020.106480_b0255","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.intimp.2020.106480_b0260","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jaad.2019.05.098","article-title":"Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare","volume":"82","author":"Damsky","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2020.106480_b0265","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-2845","article-title":"Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis","volume":"143","author":"Huang","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.intimp.2020.106480_b0270","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-213554","article-title":"Tofacitinib in steroid-dependent relapsing polychondritis","volume":"78","author":"Meshkov","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2020.106480_b0275","article-title":"Case report: Successful treatment of refractory sapho syndrome with the jak inhibitor tofacitinib","volume":"97","author":"Yang","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.intimp.2020.106480_b0280","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/rheumatology\/key384","article-title":"Tofacitinib for familial mediterranean fever: A new alternative therapy?","volume":"58","author":"Garcia-Robledo","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2020.106480_b0285","first-page":"88","article-title":"Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial mediterranean fever","volume":"42","author":"Gok","year":"2017","journal-title":"Acta Reumatol. Port"},{"issue":"1","key":"10.1016\/j.intimp.2020.106480_b0290","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s10875-019-00690-9","article-title":"STING-associated vasculopathy with onset in infancy in three children with new clinical aspect and unsatisfactory therapeutic responses to tofacitinib","volume":"40","author":"Tang","year":"2020","journal-title":"J. Clin. Immunol."},{"issue":"1396\u20139","key":"10.1016\/j.intimp.2020.106480_b0295","article-title":"Tofacitinib relieves symptoms of stimulator of interferon genes (sting)-associated vasculopathy with onset in infancy caused by 2 de novo variants in tmem173","volume":"139","author":"Seo","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2020.106480_b0300","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/art.41107","article-title":"Innately adaptive or truly autoimmune: is there something unique about systemic juvenile idiopathic arthritis?","volume":"72","author":"Kessel","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2020.106480_b0305","doi-asserted-by":"crossref","first-page":"E84","DOI":"10.3390\/biomedicines6030084","article-title":"Relapsing polychondritis: an updated review","volume":"6","author":"Borgia","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.intimp.2020.106480_b0310","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10067-018-4299-4","article-title":"Adverse drug events associated with 5mg versus 10mg tofacitinib (janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: a systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Huang","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2020.106480_b0315","first-page":"430","article-title":"Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two phase 2 randomised controlled trials","volume":"34","author":"Wallenstein","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2020.106480_b0320","doi-asserted-by":"crossref","unstructured":"Deodhar A, Chakravarty SD, Cameron C, Peterson S, Hensman R, Fogarty S, et al. Asystematicreview and networkmeta-analysisof current and investigational treatments for active ankylosing spondylitis. Clin. Rheumatol. 2020 (in press).","DOI":"10.1007\/s10067-020-04970-3"},{"key":"10.1016\/j.intimp.2020.106480_b0325","doi-asserted-by":"crossref","unstructured":"Sepriano A, Kerschbaumer A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2020 (in press).","DOI":"10.1136\/annrheumdis-2019-216653"},{"key":"10.1016\/j.intimp.2020.106480_b0330","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2020.106480_b0335","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13075-018-1539-6","article-title":"Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study","volume":"20","author":"Machado","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2020.106480_b0340","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","article-title":"Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials","volume":"17","author":"Strand","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2020.106480_b0345","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2020.106480_b0350","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semarthrit.2017.02.007","article-title":"Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis","volume":"47","author":"Maneiro","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.intimp.2020.106480_b0355","unstructured":"European Medicines Agency (EMA). Xeljanz to be used with caution for all patients at high risk of blood clots, 2019EMA\/584781\/2019. Available: https:\/\/www ema europa eu\/en\/documents\/referral\/xeljanz-article-20-procedure-xeljanz-be-used-caution-all-patients-high-risk-blood-clots_en pdf."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920302460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920302460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:22:02Z","timestamp":1761585722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920302460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":71,"alternative-id":["S1567576920302460"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106480","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The off-label uses profile of tofacitinib in systemic rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106480"}}